The “sleeper” issue in medicine: Clem Tisdell's academic scribbling on the economics of antibiotic resistance

International Journal of Social Economics

Volumn 25, Issue 6/7/8, 1998, Pages 956-967

  Doessel, D P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2942740095     PISSN: 03068293     EISSN: None     Source Type: Journal    
DOI: 10.1108/03068299810212397     Document Type: Article

References (36)

1. Bickel, L. (1972), Rise Up to Life, Charles Scribner, New York, NY.
2. Dales, J.H. (1968), Pollution, Property and Prices: An Essay in Policy-Making and Economics, University of Toronto Press, Toronto.
3. de Kruif, P. (1927), Microbe Hunters, Jonathan Cape, London.
4. Del Mar, C. (1992a), “Managing sore throat: a literature review I - making the diagnosis”, The Medical Journal of Australia, Vol. 156, 20 April, pp. 572-5.
5. Del Mar, C. (1992b), “Managing sore throat: a literature review II - do antibiotics confer benefit?”, The Medical Journal of Australia, Vol. 156, 4 May, pp. 644-9.
6. Gordon, H.S. (1954 “The economic theory of a common property resource: the fishery”, The Journal of Political Economy, Vol. LXII No. 2, pp. 124-42.
7. Hardin, G. (1968), “The tragedy of the commons”, reprinted in Enthoven A.C. and Freeman, A.M. (Eds) (1973), Pollution, Resources and the Environment, Norton, New York, NY, pp. 1-13.
8. Harvey, K. (1988), “Antibiotic use in Australia”, Australian Prescriber, Vol. 11 No. 4, pp. 74-7.
9. Harvey, R. (1981), “The economics of the pharmaceutical drug industry: the significance of the Ralph Report recommendations”, in Tatchell, P.M. (Ed.) (1981), Economics and Health: 1980 Proceedings of the Second Australian Conference of Health Economics, Health Research Project, Canberra, pp. 59-96.
10. Harvey, R. (1984 “The effect of variations in patient contribution, income and doctor supply on the demand for PBS drugs”, in Tatchell, P.M. (Ed.) (1984), Economics and Health: 1983 Proceedings of the Fifth Australian Conference of Health Economists, Health Research Project, Canberra, pp. 27-57.
11. Helms, R.B. (Ed.) (1981), Drugs and Health: Economic Issues and Policy Objectives, American Economic Institute, Washington, DC.
12. Hicks, J.R. (1946), Value and Capital, 2nd ed., Oxford University Press, London.
13. Keynes, J.M. (1936), The General Theory of Employment, Interest and Money, Macmillan, London.
14. Krantz, J.C. (1974), Historical Medical Classics Involving New Drugs, Williams and Wilkins, Baltimore, MD.
15. Lancaster, K.J. (1966a), “A new approach to consumer theory”, The Journal of Political Economy, Vol. 76 No. 2, pp. 132-57.
16. Lancaster, K.J. (1966b), “Change and innovation in the technology of consumption”, The American Economic Review, Vol. LVI No. 2, pp. 14-23.
17. Levy, S.B. (1992), The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle, Plenum Press, New York, NY.
18. Luce, R.D. and Raiffa, H. (1957), Games and Decisions: Introduction and Critical Surveys, Wiley, New York, NY.
19. Macfarlane, G. (1984), Alexander Fleming: The Man and the Myth, Harvard University Press, Cambridge, MA.
20. Maurois, A. (1959), The Life of Sir Alexander Fleming: Discoverer of Penicillin, Jonathan Cape, London.
21. Meade, J.E. (1973), The Theory of Economic Externalities: The Control of Environmental Pollution and Similar Social Costs, Sijthoff, Leiden.
22. Mishan, E.J. (1981), Introduction to Normative Economics, Oxford University Press, New York, NY.
23. North, R. and Gorman, T. (1990), Chickengate: An Independent Analysis of the Salmonella in Eggs Scare, Institute of Economic Affairs, London.
24. Nutbeam, D., Wise, M., Bauman, A., Harris, E. and Leeder, S. (1993), Goals and Targets for Australia's Health in the Year 2000 and Beyond, Report for the Commonwealth Department of Health, Housing and Community Services, University of Sydney, Sydney.
25. O'Brien, B. (1989), “The effect of patient changes on the utilisation of prescription medicines”, Journal of Health Economics, Vol. 8 No. 1, pp. 109-32.
26. OECD (1985), Measuring Health Care: Expenditure, Costs and Performance, OECD, Paris.
27. Phelps, C.E. (1989), “Bug/drug resistance”, Medical Care, Vol. 27 No. 2, pp. 194-203.
28. Pindyck, R.S. and Rubinfeld, D.L. (1992), Microeconomics, 2nd ed., Macmillan, New York, NY.
29. Schoub, B.D. (1994), AIDS and HIV in Perspective: A Guide to Understanding the Virus and Its Consequences, Cambridge University Press, Cambridge.
30. Shilts, R. (1988), And the Band Played On: Politics, People and the AIDS Epidemic, Penguin, Harmondsworth.
31. Tisdell, C. (1982 “Exploitation of techniques that decline in effectiveness with use”, Public Finance/Finances Publiques, Vol. XXXVII No. 3, pp. 428-37.
32. Victorian Medical Postgraduate Foundation (1996), Antibiotic Guidelines, 9th ed., Victorian Medical Postgraduate Foundation, Melbourne.
33. Wallace, R. (1987 “The industries assistance commission's report on pharmaceutical products”, reprintedr in Butle, J.R.G. and Doessel, D.P. (Eds) (1989), Health Economics: Australian Readings, Australian Professional Publications, Sydney, pp. 348-62.
34. Weatherall, M. (1990), In Search of a Cure: A History of Pharmaceutical Discovery, Oxford University Press, Oxford.
35. Weatherall, M. (1993), “Drug therapies”, in Bynum, W.F. and Porter, R. (Eds) (1993), Companion Encyclopaedia of the History of Medicine, Vol. 2, Routledge, London, pp. 915-39.
36. Williams, T.I. (1984), Howard Florey: Penicillin and After, Oxford University Press, Oxford.